Nifty Pharma

The NIFTY Pharma Index reflects the behaviour and performance of the pharmaceutical sector in India. The index has a maximum of 20 stocks since the last amendment effective from 30th September 2021. The NIFTY Pharma stocks are calculated using the free-float market capitalization method and can be used for benchmarking fund portfolios, among other utilization for investors. The index was launched in July 2005; the base date being 1st January 2001 with a base value of 1000. Index is re-balanced on semi-annual basis. The cut-off date is January 31 and July 31 of each year. When rebalancing, the weightage of each stock in the index is calculated such that no single stock has a weightage of more than 33%, and that of top 3 stocks cumulatively shall not be more than 62%.

ICICI Securities Ltd.( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Mumbai - 400025, India, Tel No:- 022 - 2288 2460, 022 - 2288 2470. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code:-07730) and BSE Ltd (Member Code :103) and having SEBI registration no. INZ000183631. SEBI research analyst Registration no.-INH000000990. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The non-broking products / services like Mutual Funds, Insurance, FD/ Bonds, loans, PMS, Tax, Elocker, NPS, IPO, Research, Financial Learning etc. are not exchange traded products / services and ICICI Securities Ltd. is just acting as a distributor/ referral Agent of such products / services and all disputes with respect to the distribution activity would not have access to Exchange investor redressal or Arbitration mechanism.